Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Placebo to LTP001 00mg hard gelatin capsule, LTP001, LTP001, Placebo to LTP001 00mg hard gelatin capsule
Novartis Pharmaceuticals
Part A: Healthy volunteers (Part A is not applicable to the EU; for information only) Part B: pulmonary arterial hypertension
1 trial -
Placebo to MAS825 100 mg/1 mL Concentrate for solution for infusion / Solution for injection, -, CICLOSPORIN , MAS825
Novartis Pharmaceuticals
Autoinflammatory diseases including NLRC4-Gain of Function (GOF) also known as AIFEC (autoinflammation with infantile enterocolitis), X-linked Inhibitor of Apoptosis Protein (XIAP) deficiency, or Cell division control protein 42 homolog (CDC42) mutation.
1 trial -
Placebo to TQJ230 80 mg/0.8 mL Solution for injection in pre-filled syringe with needle safety device, TQJ230
Novartis Pharmaceuticals
Calcific Aortic Valve Stenosis
1 trial -
Placebo to match ACP-204
Lacuna Pharma Pty Ltd
Alzheimer Disease psychosis
1 trial -
Placebo to match ALKS 2680, ALKS 2680, ALKS 2680, ALKS 2680
Alkermes Pharma Ireland
Narcolepsy Type 1
1 trial -
Placebo to match ALKS 2680, ALKS 2680, ALKS 2680, ALKS 2680
Alkermes Pharma Ireland
Narcolepsy Type 2
1 trial -
Placebo to match IMP TEV-56286, Emrusolmin
Lacuna Pharma Pty Ltd
Multiple System Atrophy
1 trial -
Placebo to match buloxibutid oral capsules, Buloxibutid
Lacuna Pharma Pty Ltd
idiopathic pulmonary fibrosis
1 trial -
Placebo, EP262, -, EP262
Lacuna Pharma Pty Ltd
Chronic Spontaneous Urticaria
1 trial -
Placebo, Vacuna Phleum pratense 3000 TBU/ml, Vacuna Phleum pratense 1000 TBU/ml, Test de provocaciΓ³n nasal Phleum pratense, Vacuna Phleum pratense 6000 TBU/ml
Lacuna Pharma Pty Ltd
Allergic rhinitis/rhinoconjunctivitis caused by grass polen allergy
1 trial -
Placebo: Normal Saline - Solution for injection, Daxdilimab
Elan Pharma International
Primary Discoid Lupus Erythematosus
1 trial -
Pluvicto 1 000 MBq/mL solution for injection/infusion, Locametz 25 micrograms kit for radiopharmaceutical preparation
Novartis Pharmaceuticals
Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) with moderate and severe renal impairment and with normal renal function.
1 trial -
PolyCore
Lacuna Pharma Pty Ltd
End-Stage Kidney Disease
1 trial -
Povetacicept
Vertex Pharmaceuticals (Australia) Pty.
Myasthenia Gravis, Generalized
1 trial -
Pre-operative chemotherapy
Nanjing Zenshine Pharmaceuticals
Gastric Cancers
1 trial -
Prednisolon 5 mg JENAPHARM, SPI-62_DF2, Capsule, hard for oral use as placebo for prednisolone., Film-coated tablet for oral use as placebo for Clofutriben (SPI-62)., SPI-62_DF1
Lacuna Pharma Pty Ltd
Polymyalgia rheumatica (PMR)
1 trial -
Preservative-free, ophthalmic solution
Laboratoire HRA Pharma
Paediatric myopia
1 trial -
Prograf 5 mg hard capsules, Prograf 5 mg/ml concentrate for solution for infusion, AT-1501 190 mg Vial, Prograf 0.5 mg hard capsules, Prograf 1 mg hard capsules
Eledon Pharmaceuticals
Prophylaxis of Renal Allograft Rejection
1 trial -
Provisc
AEON Biopharma
Steroid Induced Glaucoma
1 trial -
Psilocybin 25 mg Capsules, TRITTICO 60 mg/ml gocce orali, soluzione, PCB2 (Placebo of psilocybin 25mg), Trazodone placebo (pharmaceutical master preparation prepared according to the Good Pharmacy Practice)
Pari Pharma GmbH
Treatment-resistant depression
1 trial -
Public title :A Phase 1b/2a trial to evaluate Invobenitug also known as Procizumab (PCZ; AK1967) in critical cardiovascular care.
Lacuna Pharma Pty Ltd
Cardiogenic shock due to Acute Coronary Syndrome, cardiogenic shock of septic origin or cardiogenic shock due to Acute decompensated Heart Failure
1 trial -
QBW251
Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
1 trial -
QGC001
Quantum Biopharma
Heart Failure
1 trial -
QGC001
Quantum Biopharma
Essential Hypertension
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources